Therapy innovation for the treatment of pancreatic neuroendocrine tumors

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL.2, 2012, Pages

  Riccardi, Ferdinando ^a   Rizzo, Mimma ^b   Festino, Lucia ^b   Ambrosio, Francesca ^b   Molino, Carlo ^a   Uomo, Generoso ^a   Cartenì, Giacomo ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

angiogenesis; everolimus; molecular target; mTOR; pancreatic NET; somatostatin analog; sunitinib

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CHLOROZOTOCIN; DACARBAZINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; STEM CELL FACTOR; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN RECEPTOR; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER RECURRENCE; CARCINOID; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL TUMOR; HUMAN; INFECTION; LIFE EXPECTANCY; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RASH; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84858979414     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.665880     Document Type: Article

References (104)

1. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-500 (Pubitemid 350160130)
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "Carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72
3. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76
4. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004;1014:13-27 (Pubitemid 38594787)
5. Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005;19:491-505
6. Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008;19:903-8 (Pubitemid 351627305)
7. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-33
8. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-62 (Pubitemid 47497934)
9. Chatzipantelis P, Konstantinou P, Kaklamanos M, et al. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology. Cancer Cytopathol 2009;117:211-16
10. Bosman F, Carneiro F, Hruban R, Theise N. editors. WHO Classification of Tumours of the Digestive System. 4th edition. IARC Press; Lyon, France: 2010
11. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors. A review of nomenclature, grading, and staging systems. Pancreas 2010;39:707-12
12. Hill JS, McPhee JT, McDade TP. Zheng Zhou, et al. Pancreatic neuroendocrine tumors the impact of surgical resection on survival. Cancer 2009;115:741-51
13. Knigge U, Hansen CP, Stadil F. Interventional treatment of neuroendocrine liver metastases. Surgeon 2008;6:232-9
14. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130:677-82
15. Kidd M, Modlin IM. Small intestinal neuroendocrine cell pathobiology: 'carcinoid' tumors. Curr Opin Oncol 2011;23:45-52
16. Burnik FS, Yalcin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy 2009;55:381-5
17. Wang Q, Fang WH, Krupinski J, et al. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med 2008;12:2281-94
18. Sosa-Pineda B. The gene Pax4 is an essential regulator of pancreatic betacell development. Mol Cells 2004;18:289-94 (Pubitemid 40298022)
19. Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 expression in well differentiated pancreatic endocrine tumors: correlation with clinic-pathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol 2010;34:723-9
20. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-92 (Pubitemid 41815799)
21. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92
22. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309 (Pubitemid 41443415)
23. Inoue M, Hager JH, Ferrara N, et al. VEGF-A has a critical, non redundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1:193-202 (Pubitemid 41039165)
24. Fjallskog ML, Lejonklou MH, Oberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-73 (Pubitemid 36418403)
25. Fjallskog ML, Hessman O, Eriksson B, Janson ET. Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 2007;46:741-6 (Pubitemid 47123755)
26. Moreno A, Akcakanat A, Munsell MF, et al. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008;15:257-66 (Pubitemid 351449744)
27. Hansel DE, Rahman A, Hermans J, et al. Liver metastases arising from well differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 2003;16:652-9 (Pubitemid 36871497)
28. Turner HE, Harris AL, Melmed S, et al. Angiogenesis in endocrine tumors. Endocr Rev 2003;24:600-32 (Pubitemid 37330584)
29. Terris B, Scoazec JY, Rubbia L. Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 1998;32:133-8 (Pubitemid 28126179)
30. La Rosa S, Uccella S, Finzi G, et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003;34:18-27 (Pubitemid 36160017)
31. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995; 9:1760-70
32. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus40 oncogenes. Nature 1985;315:115-22 (Pubitemid 15064530)
33. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61 (Pubitemid 19115892)
34. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors,flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995;9:1760-70
35. Bergers G, Javaherian K, Lo KM, et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12 (Pubitemid 29291347)
36. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52 (Pubitemid 46202314)
37. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21 (Pubitemid 44511625)
38. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
39. Franco M, Roswall P, Cortez E, et al. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011;118:2906-17
40. Franco M, Paez-Ribes M, Cortez E, et al. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res 2011;43:884-9
41. Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 2010;28:4425-33
42. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon Alfa-2b. J Clin Oncol 2008;26:1316-23
43. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10 (Pubitemid 37328844)
44. Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol 2004;14:139-45 (Pubitemid 38234756)
45. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003;314:15-23 (Pubitemid 37409909)
46. Pietras K, Sjoblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439-43 (Pubitemid 38340290)
47. Lindahl P, Bostrom H, Karlsson L, et al. Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr Top Pathol 1999;93:27-33
48. Abramsson A, Lindblom P, Betsholtz C. Endothelial and non endothelial sources of PDGFB regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003;112:1142-51 (Pubitemid 38056291)
49. Lindblom P, Gerhardt H, Liebner S, et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003;17:1835-40 (Pubitemid 36944561)
50. Furuhashi M, Sjoblom T, Abramsson A, et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004;64:2725-33 (Pubitemid 38500608)
51. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65 (Pubitemid 29053133)
52. Sundberg C, Kowanetz M, Brown LF, et al. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 2002;82:387-401 (Pubitemid 34311112)
53. Gerhardt H, Wolburg H, Redies C. N-cadherin mediates pericytic- endothelial interaction during brain angiogenesis in the chicken. Dev Dyn 2000;218:472-9 (Pubitemid 30461783)
54. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37 (Pubitemid 36109749)
55. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8
56. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-66 (Pubitemid 38019277)
57. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605 (Pubitemid 36857948)
58. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for Sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-45 (Pubitemid 47338181)
59. Yao J, Sennino B, Davis RB, et al. Combined anti-VEGFR and anti-PDGFR actions of Sunitinib on blood vessels in preclinical tumor models [abstract]. Eur J Cancer 2006;4(Suppl):27-8
60. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35 (Pubitemid 46630490)
61. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10
62. Raymond E, Dahan L, Raoul JL, et al. Sunitinib Malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
63. Van Cutsem E, Seitz JF, Raoul J, et al. Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo. ASCO Meeting Abstract; 3 February 2011. p. 249
64. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010;28:245-55
65. Roldo C, Missiaglia E, Hagan J, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24:4677-84 (Pubitemid 46630931)
66. Yao JC, Rindi G, Evans DB. Pancreatic endocrine tumors. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 8th edition. Wolters Kluwer/Lippincott Williams & Wilkins; Philadelphia: 2008. p. 1702-21
67. Ferrer-Garcia JC, Tolosa-Torrens M, Hernando-Melia C, et al. Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and non resectable malignant insulinoma. Endocr Pract 2011;17:e17-20
68. Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009;27:193-8
69. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with Everolimus. N Engl J Med 2009;360:195-7
70. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (Everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-18
71. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral Everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76
72. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23
73. Hobday TJ, Capdevila J, Saletan S, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Multivariate analysis of progression-free survival from the RADIANT-3 trial. ASCO Meeting Abstracts; 9 June 2011. p. e21091
74. De Vries E, Anthony LB, Sideris L, et al. Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. ASCO Meeting Abstracts; 9 June 2011. p. 10624
75. Kulke MH, Blaszkowsky L, Zhu A, et al. Phase I/II study of everolimus(RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET) [abstract]. 2010 Gastrointestinal Cancers Symposium; 2010. p. 127
76. Kulke MH, Chan JA Bergsland EK. New treatment options for advanced neuroendocrine tumors. ASCO 2011 Educational Book, p. 137-43. Mill Road, Alexandria, VA
77. Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol 2011;12(2):136-48
78. Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 2011;30(Suppl 1):3-7
79. Wiedenmann B, Pavel ME, Kos-Kudla B. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology 2011;94:177-90
80. Pavel ME, Wiedenmann B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res 2011;43:844-53
81. Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010;37:594-618
82. Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. Editorial. N Engl J Med 2011;364:564-5
83. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b. J Clin Oncol 2008;26:1316-23
84. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitnib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10
85. Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 2007;25(18s suppl):abstract 4505
86. Phan A, Yao JC, Fogelman D, et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010;28(18s suppl):abstract 4044
87. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006;13:535-40 (Pubitemid 43886675)
88. Pavel ME, Bartel C, Heuck F, et al. Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). J Clin Oncol 2008;26:abstract
89. Hobday TJ, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients (pts)with progressive metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol 2006;24:abstract
90. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-23
91. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76
92. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;6:1148-54 (Pubitemid 44660065)
93. Panzuto F, Di Fonzo M, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 2006;17:461-6 (Pubitemid 43329584)
94. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with theradiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30
95. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 1992;326:519-23
96. Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12:1139-43 (Pubitemid 32834496)
97. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6 (Pubitemid 46630459)
98. Kulke MH, Stuart K, Earle C, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(18s suppl):abstract 4044
99. Kulke MH, Blaszkowsky L, Zhu A, et al. Phase I/II study of everolimus(RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET) [abstract]. 2010 Gastrointestinal Cancers Symposium; 2010. p. 127
100. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71
101. Kulke M, Hornick J, Frauenhoffer C, et al. O6-methylguanine DNAmethyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-45
102. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-91 (Pubitemid 46849574)
103. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2010;117:268-75
104. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase III study. Lancet 2011;378:2005-12